drugset
drugset / Trial / NCT01841619

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

NCT01841619 ↗

Phase 0 Completed 16 enrolled University of California, Irvine Grifols Therapeutics LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.

Timeline

Start
2013-03
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Immune Globulin Intravenous (Human) Protein / enzyme biologic 500 mg/kg Intravenous

Indications

cutaneous lupus erythematosus